Halostachine

Halostachine

SCHEMBL210960

CNCC(O)c1ccccc1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
HIF1A Q16665 4/20 0.67
BLM P54132 3/20 0.67
TDP1 Q9NUW8 3/20 0.67
HTR1A P08908 2/20 0.67
TAAR1 Q96RJ0 2/20 0.67
ALDH1A1 P00352 2/20 0.67
THPO P40225 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
NMUR2 Q9GZQ4 1/20 0.67
CYP2C9 P11712 1/20 0.67
SLC6A3 Q01959 3/20 0.63
ADRB2 P07550 3/20 0.63
ADRB1 P08588 2/20 0.63
ADRA2A P08913 2/20 0.63
ADRB3 P13945 2/20 0.63
TSHR P16473 2/20 0.63
ADRA2B P18089 2/20 0.63
ADRA2C P18825 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Halostachine SCHEMBL5076853 1.00 KDM4E (0.68) KDM4EL3MBTL1HIF1ABLMTDP1
Halostachine SCHEMBL11007060 1.00 KDM4E (0.68) KDM4EL3MBTL1HIF1ABLMTDP1
Halostachine SCHEMBL932123 1.00 KDM4E (0.68) KDM4EL3MBTL1HIF1ABLMTDP1
Halostachine SCHEMBL30473042 0.98 KDM4E (0.65) KDM4EL3MBTL1HIF1ABLMTDP1
Halostachine SCHEMBL28853304 0.92 HIF1A (0.75) KDM4EL3MBTL1HIF1ABLMTDP1
Halostachine SCHEMBL18329334 0.90 KDM4E (0.57) KDM4EL3MBTL1HIF1ABLMTDP1
Halostachine SCHEMBL5073538 0.90 KDM4E (0.62) KDM4EL3MBTL1HIF1ABLMTDP1
Halostachine SCHEMBL5075636 0.90 KDM4E (0.62) KDM4EL3MBTL1HIF1ABLMTDP1
Halostachine SCHEMBL18329341 0.87 KDM4E (0.53) KDM4EL3MBTL1HIF1ABLMTDP1
SCHEMBL7066920 0.83 KDM4E (0.63) KDM4EL3MBTL1HIF1ABLMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021256679-A1 PREPARATION METHOD OF 3-[(4S)-8-BROMO-1-METHYL-6-(2-PYRIDINYL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPINE-4-YL]PROPIONIC ACID METHYL ESTER 하나제약 주식회사 2021-12-23 WO claimed
US-9526793-B1 Salts of phenylethylamines and inorganic acids and methods of use thereof KRAMER RONALD (US) 2016-12-27 US claimed
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP claimed
US-8841347-B2 Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use UNIWERSYTET JAGIELLONSKI (PL) 2014-09-23 US claimed
US-8633251-B2 Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use UNIWERSYTET JAGIELLONSKI (PL) 2014-01-21 US claimed
US-20130289118-A1 DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE UNIWERSYTET JAGIELLONSKI (PL) 2013-10-31 US claimed
EP-1732896-B1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMA INC (US) 2012-12-12 EP claimed
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-08-09 US claimed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US claimed
CN-102272133-A Modulators of amyloid beta 2011-12-07 CN claimed
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2003-05-15 US claimed
US-6417195-B1 LIBRARIES AND COMBINATORIAL CHEMISTRY LION BIOSCIENCE AG (DE) 2002-07-09 US claimed
EP-1155001-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 2001-11-21 EP claimed
WO-2000050406-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES LION BIOSCIENCE AG (DE) 2000-08-31 WO claimed
EP-0863877-A4 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TORREY PINES INST (US) 1999-07-21 EP claimed
US-5874443-A BIOSYNTHESIS TREGA BIOSCIENCES, INC. (US) 1999-02-23 US claimed
EP-0863877-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1998-09-16 EP claimed
WO-1997016428-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1997-05-09 WO claimed
US-5468486-A Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1995-11-21 US claimed
US-4085270-A Sympathicomimetic acyloxy-phenylethanolamine CHEMISCH-PHARMAZEUTISCHE FABRIK ADOLF KLINGE & CO. (DT) 1978-04-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP2, PARP3 KDM4E 1262/4885L3MBTL1 2343/4885HIF1A 1443/4885
US-20130289118-A1 DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE SCN1A, SCN3A, ACHE KDM4E 2309/4885L3MBTL1 3706/4885HIF1A 2111/4885
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 KDM4E 3549/4885L3MBTL1 1286/4885HIF1A 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.